Publications by authors named "Leisl Packer"

Claim this Profile
D
Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R.
Ben Markman, Steven Kao, Nick Pavlakis, Victoria Bray, Leisl Packer

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Vanessa F Bonazzi, Olga Kondrashova, Deborah Smith, Katia Nones, Asmerom T Sengal, Leisl M Packer

Genome Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
Leisl M Packer, Samantha J Stehbens, Vanessa F Bonazzi, Jennifer H Gunter, Robert J Ju

Mol Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Endometrial Cancers.
Leisl M Packer, Xinyan Geng, Vanessa F Bonazzi, Robert J Ju, Clare E Mahon

Mol Cancer Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.
Leisl M Packer, Pamela M Pollock

Cancer Discov· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Leisl M Packer, Sareena Rana, Robert Hayward, Thomas O'Hare, Christopher A Eide

Cancer Cell· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia.
Leisl Packer, Richard Marais

Cancer Cell· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.
Imanol Arozarena, Berta Sanchez-Laorden, Leisl Packer, Cristina Hidalgo-Carcedo, Robert Hayward

Cancer Cell· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
Peter L J de Keizer, Leisl M Packer, Anna A Szypowska, Paulien E Riedl-Polderman, Niels J F van den Broek

Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Jonathan R Dry, Sandra Pavey, Christine A Pratilas, Chris Harbron, Sarah Runswick, Leisl Packer

Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
Leisl M Packer, Philip East, Jorge S Reis-Filho, Richard Marais

Pigment Cell Melanoma Res· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma.
Wieke Zuidervaart, Sandra Pavey, Frans A van Nieuwpoort, Leisl Packer, Coby Out

Melanoma Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.
Leisl M Packer, Sandra J Pavey, Glen M Boyle, Mitchell S Stark, Ana L Ayub

Int J Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Leisl Packer, Sandra Pavey, Andrew Parker, Mitchell Stark, Peter Johansson

Carcinogenesis· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma.
Sandra Pavey, Wieke Zuidervaart, Frans van Nieuwpoort, Leisl Packer, Martine Jager

Melanoma Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of the cell surface mucin gene family in adenocarcinomas.
Leisl M Packer, Stephanie J Williams, Shirley Callaghan, David C Gotley, Michael A McGuckin

Int J Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Sandra Pavey, Peter Johansson, Leisl Packer, Jennifer Taylor, Mitchell Stark

Oncogene· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of MUC1 splice variants in benign and malignant ovarian tumours.
Andreas Obermair, Bernd C Schmid, Leisl M Packer, Sepp Leodolter, Peter Birner

Int J Cancer· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis